DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL
- PMID: 38724656
- DOI: 10.1007/s00277-024-05790-0
DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL
Abstract
Chimeric antigen receptor T (CAR-T) cells therapy is a milestone achievement in the immunotherapy of relapsed and refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). However, some patients treated with CAR-T cells do not achieve complete remission, the mechanisms of which have not been elucidated. In the present study, we report a 9-year-old pediatric patient with refractory B-ALL received a triple infusion of autologous CD19 CAR-T cells therapy after the second relapse. CAR-T cells expanded in the peripheral blood and bone marrow. However, the patient did not achieve complete remission, indicating a lack of response to CAR-T cells therapy. Analysis of etiological factors revealed that the number of CD4 and CD8 double-negative T (DNT) cells was significantly upregulated in the peripheral blood, bone marrow, and autologous CAR-T cells products. In conclusiont, these findings indicate that DNT cells mediated resistance to CAR-T cells therapy in this pediatric patient with R/R B-ALL.
Keywords: Acute lymphoblastic leukemia; CD4 and CD8 double-negative T cells; Chimeric antigen receptor T cells; Relapsed and refractory.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.Clin Cancer Res. 2021 May 15;27(10):2764-2772. doi: 10.1158/1078-0432.CCR-20-3863. Epub 2021 Feb 24. Clin Cancer Res. 2021. PMID: 33627493 Clinical Trial.
-
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8. J Hematol Oncol. 2020. PMID: 32894185 Free PMC article. Clinical Trial.
-
Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.Chin Med J (Engl). 2020 Feb 20;133(4):474-482. doi: 10.1097/CM9.0000000000000638. Chin Med J (Engl). 2020. PMID: 31977556 Free PMC article. Review.
-
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33573914
-
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020. Front Immunol. 2020. PMID: 32849662 Free PMC article. Review.
References
-
- Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM (2023) Reprogramming T cell differentiation and exhaustion in CAR-T cells therapy. Journal of Hematology & Oncology 16(1):108. doi:https://doi.org0.1186/s13045-023-01504-7
-
- Gumber D, Wang LD (2022) Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. Ebiomedicine 77:103941. https://doi.org/10.1016/j.ebiom.2022.103941 - DOI - PubMed - PMC
-
- Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem H-P, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652–1663. https://doi.org/10.1182/blood-2018-11-883710 - DOI - PubMed - PMC
-
- Liu Y, Liu G, Wang J, Zheng Z-Y, Jia L, Rui W, Huang D, Zhou Z-X, Zhou L, Wu X, Lin S, Zhao X, Lin X (2021) Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med 13(586):51–91. https://doi.org/10.1126/scitranslmed.abb5191 - DOI
-
- Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng W-K, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27(8):1419–1431. https://doi.org/10.1038/s41591-021-01436-0 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials